STK4 protein expression pattern follows different trends in endometrioid and serous endometrial adenocarcinoma upon tumor progression

Sci Rep. 2022 Dec 22;12(1):22154. doi: 10.1038/s41598-022-26391-9.

Abstract

In a previous study, we showed that serine/threonine-protein kinase 4 (STK4) is involved in the control on proliferation and migration of endometrial cancer (EC) cells in vitro. In the present paper, we studied STK4 expression in EC tissues from a large cohort of patients to determine whether STK4 can serve as a marker for the aggressiveness and prognosis of EC. Tissue samples from patients with EC were examined for tumor type, grade, and stage. The STK4 protein expression in EC cells was assessed by immunohistochemistry and related to clinicopathological data of patients, such as progression and patient survival rate. The STK4 mRNA levels and its relation to the survival rate were analyzed also in publicly available databases. The STK4 gene expression was low at both, the mRNA and protein levels in EC, especially in serous tumors. Comparison of STK4 expression with the patient survival rate shows that the higher expression is associated with worse prognosis in serous EC, while no such dependence was found in endometrioid EC. Hence, the determination of the SKT4 expression pattern could be used as a putative prognostic marker for serous EC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Endometrioid* / pathology
  • Cystadenocarcinoma, Serous* / genetics
  • Cystadenocarcinoma, Serous* / pathology
  • Endometrial Neoplasms* / pathology
  • Endometrium / metabolism
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Prognosis
  • Protein Serine-Threonine Kinases / genetics

Substances

  • STK4 protein, human
  • Protein Serine-Threonine Kinases
  • Intracellular Signaling Peptides and Proteins